An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists
Tirzepatide use is associated with better outcomes in adults aged 40 years or older with T2DM, body mass index ≥25 kg/m<sup>2</sup>, and pre-existing IHD.
Authors
- Sourbha S. Dani (ORCID: https://orcid.org/0000-0002-3434-6136)
- Anju Nohria (ORCID: https://orcid.org/0000-0002-7113-1118)
- Deepak L. Bhatt (ORCID: https://orcid.org/0000-0002-1278-6245)
- Pardeep S. Jhund (ORCID: https://orcid.org/0000-0003-4306-5317)
- Javed Butler (ORCID: https://orcid.org/0000-0001-7683-4720)
- Sadeer G Al-Kindi (ORCID: https://orcid.org/0000-0002-1122-7695)
- Sumanth Khadke (ORCID: https://orcid.org/0000-0002-7262-6905)
- Sarju Ganatra (ORCID: https://orcid.org/0000-0003-0296-6864)
- Ashish Kumar
- Gregg C. Fonarow (ORCID: https://orcid.org/0000-0002-3192-8093)
- Khurram Nasir (ORCID: https://orcid.org/0000-0001-5376-2269)
- Naveed A. Sattar (ORCID: https://orcid.org/0000-0002-1604-2593)
- Mikhail Kosiborod
- Bhargav Makwana
Institutions
- Brigham and Women's Hospital (US)
- Houston Methodist (US)
- Harvard University (US)
- Ronald Reagan UCLA Medical Center (US)
- Mount Sinai Hospital (US)
- Lahey Medical Center (US)
- Baylor Medical Center at Garland (US)
- Saint Luke's Hospital (US)
- Cleveland Clinic Akron General (US)
- Research Institute of Dallas (US)
- University of Missouri–Kansas City (US)
- University of Glasgow (GB)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1016/j.jacadv.2025.101740
- Citations
- 13
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 16.83